From Dr. Laura Lubbers <[email protected]>
Subject Join us for the first "Treatment Talk"
Date July 19, 2022 3:00 PM
  Links have been removed from this email. Learn more in the FAQ.
  Links have been removed from this email. Learn more in the FAQ.
This "Treatment Talk" will focus on Lennox-Gastaut Syndrome (LGS), a severe form of childhood epilepsy that arises during infancy or early childhood

[link removed]
[link removed]

CURE Epilepsy is proud to present its inaugural “Treatment Talk” ([link removed]) , a social-media broadcast highlighting conditions related to epilepsy and options available for treatment of related seizures and their side effects. This “Treatment Talk” will focus on Lennox-Gastaut Syndrome (LGS), a severe form of childhood epilepsy that arises during infancy or early childhood, and the use of the drug fenfluramine to treat patients diagnosed with LGS. Our talk will feature Dr. Michael Chez, a pediatric neurologist at Sutter Health, and Heather Bushey, a parent whose son has LGS and is a patient of Dr. Chez. Viewers will learn more about how LGS is diagnosed, common seizure types and comorbidities associated with LGS, how fenfluramine works to reduce some of these seizure types, and any risks and benefits found in recent clinical trials featuring fenfluramine.

This "Treatment Talk" will premiere on the CURE Epilepsy Facebook page on July 25 at 12 pm CST. Be sure to mark yourself as "interested" or "going" on the premiere event page ([link removed]) to get notifications when "Treatment Talk" debuts.
Get Notified When "Treatment Talk" Premiers ([link removed])
Our mission is to find a cure for epilepsy, by promoting and funding patient-focused research. CURE is a non-profit 501(c)(3) tax-exempt organization. Our tax identification number is 36-4253176.
[link removed]
[link removed]
[link removed]
[link removed]
[link removed]
[link removed]

============================================================
Copyright © 2022 CURE Epilepsy, All rights reserved.
In the past you provided CURE Epilepsy your email address. Occasionally, you will receive updates from us about epilepsy research and news.

Our mailing address is:
CURE Epilepsy
420 Wabash Ave, Ste 650
Chicago, IL 60611
USA
Want to change how you receive these emails?
You can ** update your preferences ([link removed])
or ** unsubscribe from this list ([link removed])
.

This email was sent to [email protected] (mailto:[email protected])
why did I get this? ([link removed]) unsubscribe from this list ([link removed]) update subscription preferences ([link removed])
CURE Epilepsy . 420 Wabash Ave, Ste 650 . Chicago, IL 60611 . USA
Screenshot of the email generated on import

Message Analysis